InventisBio, Co., Ltd. Class A
SSSE:68838214.38
CNY
-1.09
(-7.05%)
ISIN
CNE100005Q22
Return %
Stock
S&P 500
1Y
-48.46
14.20
3Y
4.51
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Yao Lin Wang
- Full Time Employees
- 182
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Shanghai China
- IPO Date
- Jul 25, 2022
- Website
- inventisbio.com
- Similar Companies
- Business
- InventisBio Co., Ltd. is a commercial- and clinical-stage biopharmaceutical enterprise focused on the discovery, development, and commercialization of innovative small-molecule therapeutics targeting oncology, autoimmune diseases, and metabolic disorders. The company's therapeutic portfolio and clinical development pipeline comprise Garsorasib (marketed as Anfangning / D-1553), an orally bioavailable KRAS G12C inhibitor approved in China for adult patients with advanced non-small cell lung cancer harboring the KRAS G12C mutation; Befotertinib Mesylate, a third-generation EGFR tyrosine kinase inhibitor approved in China for the treatment of EGFR-mutant advanced non-small cell lung cancer, co-developed and commercialized in collaboration with Betta Pharmaceuticals; D-2570, an oral selective TYK2 inhibitor advancing in Phase III registration trials for moderate-to-severe plaque psoriasis; Taragarestrant (D-0502), an oral selective estrogen receptor degrader in Phase III clinical development for estrogen receptor-positive, HER2-negative advanced breast cancer; Darbinurad (D-0120), a selective URAT1 inhibitor evaluated for hyperuricemia and gout; and a series of preclinical discovery-stage programs including YF087, a WRN helicase inhibitor; YF550, a KIF18A inhibitor; and YF057, an oral STAT6 degrader. In recent operational and corporate milestones, China's National Medical Products Administration approved Garsorasib for commercial distribution and granted the molecule additional Breakthrough Therapy Designations for KRAS G12C-mutant pancreatic ductal adenocarcinoma and colorectal cancer indications; the company completed positive Phase II trials and initiated Phase III registration studies for D-2570 in autoimmune indications; the firm submitted an application for an initial public offering on the Main Board of the Hong Kong Stock Exchange to establish a dual-listing capital framework; and it expanded its strategic research alliances with global biopharmaceutical companies including MSD. Founded in 2013, InventisBio Co., Ltd. is headquartered in Shanghai, China, maintains research and clinical operations in Shanghai, Beijing, and the United States (New Jersey), and trades on the Shanghai Stock Exchange STAR Market under the ticker symbol SSE: 688382.